The Use of Folic Acid in Chronic Kidney Disease Patients With Anemia
Abstract
Chronic kidney disease (CKD) is defined as decreasing kidney function (GFR < 60 ml/minute/1.73 m2 ) for more than 3 months. Anemia is a common complication of CKD due to a decrease in the hormone erythropoietin related to hemoglobin levels. One of the anemia therapies involves using folic acid. Folic acid helps the process of nucleoprotein synthesis and erythropoiesis maintenance. The objective of this study was to determine the pattern of folic acid applied to CKD patients with anemia at University of Muhammadiyah Malang General Hospital. Observational, descriptive, and retrospective data collection methods were used. The results showed that there were 17 patients (47%) with a single use of folic acid (3x1 mg, oral); the most common pattern of the two-combination was folic acid (3x1 mg, oral) and PRC (250 ml, intravenous [iv]), which was given to 11 patients (65%); and the most common pattern of threecombination was folic acid (3x1 mg, oral), Promavit® (3x1 tab, oral), and PRC (250 ml, iv), which was given to 2 patients or 100%. Of the 16 switch patterns, the most of common combination was a single pattern of folic acid (3x1 mg, oral) and a combination of folic acid (3x1 mg, oral) and PRC (250 ml, iv), given to 7 patients (44%).
Keywords: folic acid, anemia, chronic kidney disease
References
[1] Marriot J, Cockwell P, Stringer S. Chronic Kidney Disease and End-Stage Renal Disease. In: Whittlese C, Hodson K, editors. Clinical Pharmacy and Therapeutics. Elsevier; 2019. p. 308.
[2] Trahan C, Lapeyraque AL, Sznajder M, et al. In malnourished adolescent with anorexia nervosa, Cockroft-Gault formula is the most relevant formula to estimate renal function. Clinical Nutrition. 2019.
[3] Alidadi A, Boroujeni E. Evaluating the prevalence and etiology of chronic renal failure. International Journal of Pharmaceutical and Biological Science Archive. 2018;6(3):1– 4.
[4] Nasution SH, Syarif S, Musyabiq S. Penyakit gagal ginjal kronis stadium 5 berdasarkan determinan umur, jenis kelamin, dan diagnosa etiologi di indonesia tahun 2018 chronic kidney failure disease stage 5 based on determinants of age, gender, and diagnosis of etiology in Indonesia in 201. JK Unila. 2020;4(2):157–60.
[5] Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. Am J Kidney Dis. 2019 Jul;74(1):120–31.
[6] Listiana D, Isgiyanto A, Alvionita I. “Hubungan Riwayat Diabetes Mellitus dengan Penyakit Ginjal Kronis Ruang Penyakit Dalam RSUD dr. M. Yunus Bengkulu.,” Jurnal Sains Kesehatan. vol. 24, no. No.3, pp. 1–10, 2016.
[7] Rivandi J, Yonata A. Hubungan Diabetes Melitus Dengan Kejadian Gagal Ginjal Kronik. Jurnal Majority. 2015;4(9):27–34.
[8] Yang J, He W. Chronic kidney disease: Diagnosis and treatment. Springer; https://doi.org/10.1007/978-981-32-9131-7
[9] DiPiro JT, Yee GC, Posey LM, Haines ST, Nolin TD, Elingron V. Pharmacotherapy: A pathophysiologic approach. 11th ed. McGraw Hill Education; 2020.
[10] Okorie C, Annan R, Turkey H, Akhtar N, Gray F, Hamdy K, et al. Epidemiology and management of chronic renal failure: A global public health problem. Biostatistics and Epidemiology International Journal. 2018;1(1):11–6.
[11] KDIGO. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279–335.
[12] [12] Schaefer RM, Teschner M, Kosch M. Folate metabolism in renal failure. Nephrology Dialysis Transplantation. 2014;17(5):24-27.
[13] Alvionita WD, Masruhim MA. Pengaruh penggunaan asam folat terhadap kadar hemoglobin pasien penyakit ginjal kronik yang menjalani hemodialisis di rsud abdul wahab sjahranie. Journal Trop. Pharm. Chem. 2016;3(3):179–84.
[14] Zhong H, Lin W, Zhou T. Current and Emerging Drugs in the Treatment of Anemia in Patients with Chronic Kidney Disease. Journal Of Pharmacy & Pharmaceutical Sciences. 2020;23:278-https://doi.org/10.18433/jpps30919.
[15] Chukwuonye II, Ogah OS, Anyabolu EN, Ohagwu KA, Nwabuko OC, Onwuchekwa U, et al. Prevalence of chronic kidney disease in Nigeria: Systematic review of population-based studies. Int J Nephrol Renovasc Dis. 2018 May;11(12):165–72.
[16] Shiferaw WS, Akalu TY, Aynalem YA. Risk Factors for Anemia in Patients with Chronic Renal Failure: A Systematic Review and Meta-Analysis. Ethiop J Health Sci. 2020 Sep;30(5):829–42.
[17] Gunaseelan R, Surudarma IW, Wihandani DM, Sutadarma IW. Prevalence of anemia on chronic kidney disease and its influenced factors in Sanglah General Hospital. 2015-2017, Bali. Intisari Sains Medis. 2020;11(1):248.
[18] Megawati S, Restudiarti A, Kurniasih S. Evaluation of Drug Use of Anemia in Patients Chronic Kidney Failure. Jurnal Farmagazine. 3(2):2020.
[19] Kemenkes RI, “Situasi Penyakit Ginjal Kronis,” (2017).
[20] Podestà MA, Valli F, Galassi A, et al. COVID-19 in chronic kidney disease: The impact of old and novel cardiovascular risk factors. Blood Purification. 2021.
[21] Mahmood L. The metabolic processes of folic acid and Vitamin B12 deficiency. J Health Res Rev Dev Ctries. 2014;1(1):5.
[22] Katzung BG. Basic & Clinical Pharmacology. McGraw Hill Education; 2018.